Annual Financials for Jasper Therapeutics Inc.
Fiscal year is January-December. All values USD millions. |
| | | 2020 | 2021 |
5-year trend |
Sales/Revenue
|
- | - | - | - | - | |
Sales Growth |
- | - | - | - | - | |
Cost of Goods Sold (COGS) incl. D&A |
- | - | - | 21,000 | 566,000 | |
COGS excluding D&A |
- | - | - | - | - | |
Depreciation & Amortization Expense |
- | - | - | 21,000 | 566,000 | |
Depreciation |
- | - | - | 21,000 | 566,000 | |
Amortization of Intangibles |
- | - | - | - | - | |
COGS Growth |
- | - | - | - | 2,595.24% | |
Gross Income |
- | - | - | (21,000) | (566,000) | |
Gross Income Growth |
- | - | - | - | -2,595.24% | |
Gross Profit Margin |
- | - | - | - | - | NA |
|
| | | 2020 | 2021 |
5-year trend |
SG&A Expense |
- | - | - | 20.96M | 37.36M | |
Research & Development |
- | - | - | 16.18M | 26.52M | |
Other SG&A |
- | - | - | - | - | |
SGA Growth |
- | - | - | - | 78.25% | |
Other Operating Expense |
- | - | - | - | - | |
Unusual Expense |
- | - | - | 10.88M | (6.28M) | |
EBIT after Unusual Expense |
- | - | - | (10.88M) | (31.65M) | |
Non Operating Income/Expense |
- | - | - | (111,000) | (80,000) | |
Non-Operating Interest Income |
- | - | - | - | - | |
Equity in Affiliates (Pretax) |
- | - | - | - | - | |
Interest Expense |
- | - | - | - | - | |
Interest Expense Growth |
- | - | - | - | - | |
Gross Interest Expense |
- | - | - | - | - | |
Interest Capitalized |
- | - | - | - | - | |
Pretax Income |
- | - | - | (31.97M) | (31.73M) | |
Pretax Income Growth |
- | - | - | - | 0.74% | |
Pretax Margin |
- | - | - | - | - | NA |
Income Tax |
- | - | - | (298,000) | (1.1M) | |
Income Tax - Current Domestic |
- | - | - | - | - | |
Income Tax - Current Foreign |
- | - | - | - | - | |
Income Tax - Deferred Domestic |
- | - | - | - | - | |
Income Tax - Deferred Foreign |
- | - | - | - | - | |
Income Tax Credits |
- | - | - | 298,000 | 1.1M | |
Equity in Affiliates |
- | - | - | - | - | |
Other After Tax Income (Expense) |
- | - | - | - | - | |
Consolidated Net Income |
- | - | - | (31.67M) | (30.64M) | |
Minority Interest Expense |
- | - | - | - | - | |
Net Income |
- | - | - | (31.67M) | (30.64M) | |
Net Income Growth |
- | - | - | - | 3.26% | |
Net Margin Growth |
- | - | - | - | - | NA |
Extraordinaries & Discontinued Operations |
- | - | - | - | - | |
Extra Items & Gain/Loss Sale Of Assets |
- | - | - | - | - | |
Cumulative Effect - Accounting Chg |
- | - | - | - | - | |
Discontinued Operations |
- | - | - | - | - | |
Net Income After Extraordinaries |
- | - | - | (31.67M) | (30.64M) | |
Preferred Dividends |
- | - | - | - | - | |
Net Income Available to Common |
- | - | - | (31.67M) | (30.64M) | |
EPS (Basic) |
- | - | - | (11.43) | (2.69) | |
EPS (Basic) Growth |
- | - | - | - | 76.48% | |
Basic Shares Outstanding |
- | - | - | 2.77M | 11.39M | |
EPS (Diluted) |
- | - | - | (11.43) | (2.69) | |
EPS (Diluted) Growth |
- | - | - | - | 76.48% | |
Diluted Shares Outstanding |
- | - | - | 2.77M | 11.39M | |
EBITDA |
- | - | - | (20.96M) | (37.36M) | |
EBITDA Growth |
- | - | - | - | -78.25% | |
EBITDA Margin |
- | - | - | - | - | NA |